Jonathan Yong : Hi! Thanks for taking the question here. Just kind of building on that comment you just made. You guys said that you’re over 900,000 prescribers now. Can you talk about the benefits that are being derived from that? Has that come up in pharma manufacturer solutions, in the conversations you’re having with manufacturers? And then alongside that, has that led to any increased prescription transaction revenue that maybe derived from there. Thanks.
Doug Hirsch: Thank you Jonathan, for the question. Throughout the company, providers have been extremely important to us. They’ve been an incredible channel for us. They’ve been a great referral source for patients broadly. And this is because we really provide a lot of value for them, and for their patients. This is evidenced by the over 90 NPS score that we have with them. What €“ the stat we’ve been talking about today is that with Provider Mode, which we launched last year, we have the 400,000 prescribers now activated in Provider Mode. As you alluded to, that’s out of a larger audience of prescribers who use GoodRx. But these are about 400,000 prescribers who are now activated in Provider Mode. We’re really excited about that, because we are seeing materially higher LTVs from those activated providers.
So these new tools that we’ve been building and developing for them to make their workflow even easier by incorporating GoodRx and provide others tools, they are working. And just like you are saying, we have the primary revenue that we derive from this is through the manufacturer solutions. And so we have been generalizing revenue from this offering for about a year, and that’s because we are selling within our pharma manufacturer solutions business, some deals that just target HCVs, deals that target HCVs and consumers, a variety of different things, so. But it is clear that because of our great access to providers, this is a great way for us to access that portion of the $30 billion TAM that manufacturers do spend on access and awareness, so it’s a very important piece.
There is green shoots around this second point, which is we are making tools within that Provider Mode that make it even easier for doctors to tell their patients about GoodRx to use GoodRx through transactions and that is, you know helps increase PTR revenue, making those recommendations to patients at an increased rate.
Operator: Thank you. One moment for our next question. It comes from the line of George Hill with Deutsche Bank. Your line is open.
George Hill: Hey! Good evening guys. And I appreciate you taking my question. I guess, can you guys talk about how big like as a percentage of revenue and maybe the margin impact of these direct retail contracts. I think we would assume that the margin profile on these is a little bit worse than the composite given the €“ it seems like you would have a multiple PBMs playing off each other. But would love any incremental commentary that you could make on the kind of the direct retail contracts versus the balance of the business.
Trevor Bezdek: Sure. What’s really important this €“ that we want to highlight is that we’ve made changes to make sure that we have the strongest and largest retail PBM manufacturer network in our history. One of those components is implementing this hybrid approach to contracting across the key retailers to enhance stability and strength of the network. So we are €“ have our PBM marketplace with our full set of these PBMs we work with. And then also we selectively contract in order to make sure we are meeting the needs of all the parties in the ecosystem. So we do now have direct contracts with many of our top pharmacy partners. I would highlight I think which, to what I think answers your question that take rate has remained stable since the grocer issue.
